CAS 163250-90-6

Orbofiban

Description:

Orbofiban is a synthetic chemical compound classified as a glycoprotein IIb/IIIa receptor antagonist, primarily used in the context of cardiovascular medicine. It functions by inhibiting platelet aggregation, thereby reducing the risk of thrombus formation in patients undergoing certain medical procedures or those with acute coronary syndromes. Orbofiban is characterized by its ability to selectively bind to the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen from binding and subsequently inhibiting platelet activation. The compound is typically administered intravenously and has been studied for its efficacy in improving outcomes in patients with unstable angina or those undergoing percutaneous coronary interventions. Its pharmacokinetic profile includes a relatively short half-life, necessitating careful monitoring and potential adjustment of dosing in clinical settings. As with many antiplatelet agents, potential side effects may include bleeding complications, which require consideration in patient management. Overall, Orbofiban represents a significant advancement in antiplatelet therapy, contributing to improved cardiovascular outcomes.

Formula: C₁₇H₂₃N₅O₄

InChI: InChI=1S/C17H23N5O4/c1-2-26-14(23)7-9-20-17(25)21-13-8-10-22(16(13)24)12-5-3-11(4-6-12)15(18)19/h3-6,13H,2,7-10H2,1H3,(H3,18,19)(H2,20,21,25)/t13-/m0/s1

InChI key: InChIKey=VJDOPFARMOLELX-ZDUSSCGKSA-N

SMILES: O=C1N(CC[C@@H]1NC(NCCC(OCC)=O)=O)C2=CC=C(C(=N)N)C=C2

Synonyms:

• β-Alanine, N-[[[1-[4-(aminoiminomethyl)phenyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-, ethyl ester, (S)-
• β-Alanine, N-[[[(3S)-1-[4-(aminoiminomethyl)phenyl]-2-oxo-3-pyrrolidinyl]amino]carbonyl]-, ethyl ester
• Orbofiban

Orbofiban

CAS: 163250-90-6

Orbofiban, an orally administered antagonist of the platelet GPIIb/IIIa receptor, effectively inhibits platelet aggregation.

Formula: C₁₇H₂₃N₅O₄

Color and Shape: Solid

Molecular weight: 361.4

Ref: TM-T61345